
SPRY Stock Forecast & Price Target
SPRY Analyst Ratings
Bulls say
ARS Pharmaceuticals is attractive because neffy is the first no-needle intranasal epinephrine product in the U.S. and Europe, addressing a large, growing, underserved anaphylaxis market where autoinjectors remain cumbersome, painful, and inconvenient. Management’s more disciplined launch strategy, broader payer/access work, and targeted physician engagement are already showing traction, with U.S. market share rising to 5% from 4% in 3Q25 and share in salesforce-covered accounts increasing to ~9% from ~6% a year ago. The investment case is further strengthened by ARS-2, which targets a sizeable CSU market with limited competition and meaningful pricing power, while 2026 OpEx was lowered to ~$248M and cash-flow breakeven by 2027 was reaffirmed.
Bears say
ARS Pharmaceuticals is facing a fundamental commercialization challenge because neffy’s $33.4M in 3Q sales fell short of the $38M estimate and $39M consensus, suggesting launch momentum is weaker than expected and inventory fluctuations may be masking uneven demand. Adoption has been slower in a broad, fragmented market with an entrenched low-cost standard of care, while no new July 1 formulary additions or coverage decisions removed a key near-term catalyst for uptake. Reimbursement and access remain major headwinds, as patient cost-sharing, payer resistance to a higher-priced lower-dose product, and likely slow adoption among dermatologists could continue to constrain growth and keep sentiment negative.
This aggregate rating is based on analysts' research of ARS Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRY Analyst Forecast & Price Prediction
Start investing in SPRY
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ARS Pharmaceuticals Inc (SPRY) Forecast
SPRY Analyst Forecast & Price Prediction
Start investing in SPRY
Order type
Buy in
Order amount
Est. shares
0 shares